-
Je něco špatně v tomto záznamu ?
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis
B. Wootla, JO. Watzlawik, N. Stavropoulos, NJ. Wittenberg, H. Dasari, MA. Abdelrahim, JR. Henley, SH. Oh, AE. Warrington, M. Rodriguez,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- imunosupresiva farmakologie terapeutické užití MeSH
- imunoterapie metody trendy MeSH
- lidé MeSH
- monoklonální protilátky farmakologie terapeutické užití MeSH
- roztroušená skleróza diagnóza farmakoterapie imunologie MeSH
- tvorba protilátek účinky léků imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. AREAS COVERED: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. EXPERT OPINION: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031844
- 003
- CZ-PrNML
- 005
- 20171101111321.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1517/14712598.2016.1158809 $2 doi
- 035 __
- $a (PubMed)26914737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Wootla, Bharath $u Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
- 245 10
- $a Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis / $c B. Wootla, JO. Watzlawik, N. Stavropoulos, NJ. Wittenberg, H. Dasari, MA. Abdelrahim, JR. Henley, SH. Oh, AE. Warrington, M. Rodriguez,
- 520 9_
- $a INTRODUCTION: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. AREAS COVERED: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. EXPERT OPINION: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a monoklonální protilátky $x farmakologie $x terapeutické užití $7 D000911
- 650 _2
- $a tvorba protilátek $x účinky léků $x imunologie $7 D000917
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x farmakologie $x terapeutické užití $7 D007166
- 650 _2
- $a imunoterapie $x metody $x trendy $7 D007167
- 650 _2
- $a roztroušená skleróza $x diagnóza $x farmakoterapie $x imunologie $7 D009103
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Watzlawik, Jens O $u Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA.
- 700 1_
- $a Stavropoulos, Nikolaos $u Department of General Medicine, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Simkova 870, Hradec Kralove 1, 500 38, Czech Republic.
- 700 1_
- $a Wittenberg, Nathan J $u Department of Electrical and Computer Engineering, University of Minnesota, 200 Union Street SE, 4-174 Keller Hall Minneapolis, MN 55455, USA. Department of Biomedical Engineering, University of Minnesota, 200 Union Street SE, 4-174 Keller Hall Minneapolis, MN 55455, USA.
- 700 1_
- $a Dasari, Harika $u Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
- 700 1_
- $a Abdelrahim, Murtada A $u Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. $7 gn_A_00000363
- 700 1_
- $a Henley, John R $u Department of Neurologic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
- 700 1_
- $a Oh, Sang-Hyun $u Department of Electrical and Computer Engineering, University of Minnesota, 200 Union Street SE, 4-174 Keller Hall Minneapolis, MN 55455, USA. Department of Biomedical Engineering, University of Minnesota, 200 Union Street SE, 4-174 Keller Hall Minneapolis, MN 55455, USA.
- 700 1_
- $a Warrington, Arthur E $u Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
- 700 1_
- $a Rodriguez, Moses $u Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Department of Immunology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
- 773 0_
- $w MED00181398 $t Expert opinion on biological therapy $x 1744-7682 $g Roč. 16, č. 6 (2016), s. 827-839
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26914737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171101111412 $b ABA008
- 999 __
- $a ok $b bmc $g 1255437 $s 992871
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 16 $c 6 $d 827-839 $e 20160310 $i 1744-7682 $m Expert opinion on biological therapy $n Expert Opin Biol Ther $x MED00181398
- LZP __
- $a Pubmed-20171025
